Table 1 Clinical and spirometric characteristics at baseline. Description and comparison between the three groups
Total | VIG | BIG | CG | p-value | |
|---|---|---|---|---|---|
N = 99 | N = 38 | N = 25 | N = 36 | ||
Main characteristics | |||||
Age in years, median (IQR) | 57.5 (48.6–62.0) | 57.7 (52.4–60.3) | 57.7 (46.2–62.0) | 56.3 (49.9–63.3) | 0.92 |
Masculine gender, n (%) | 64 (65) | 27 (71) | 18 (72) | 19 (53) | 0.17 |
Comorbidities at enrollment | |||||
Renal dysfunction, n (%) | 9 (9) | 8 (21) | 1 (4) | 0 (0) | 0.01 |
Diabetes mellitus, n (%) | 63 (64) | 23 (61) | 20 (80) | 20 (56) | 0.13 |
Arterial hypertension, n (%) | 53 (54) | 22 (58) | 14 (56) | 17 (47) | 0.63 |
Underlying respiratory diseases | |||||
Bronchial dilatation (%) | 6 (6) | 2 (5) | 3 (12) | 1 (3) | 0.38 |
Emphysema/COPD (%) | 30 (30) | 14 (37) | 8 (32) | 8 (22) | 0.38 |
Alpha-1 antitrypsine deficiency (%) | 8 (8) | 2 (5) | 2 (8) | 4 (11) | 0.74 |
Pulmonary fibrosis (%) | 42 (42) | 15 (40) | 10 (40) | 17 (47) | 0.77 |
Other interstitial disease (%) | 13 (13) | 5 (13) | 2 (8) | 6 (17) | 0.65 |
Immunosuppresive therapy | |||||
Tacrolimus (%) | 89 (90) | 35 (92) | 24 (96) | 30 (83) | 0.27 |
Mycophenolate mofetil (%) | 83 (84) | 31 (82) | 24 (96) | 29 (81) | 0.41 |
Graft features | |||||
Second graft (%) | 3 (3) | 2 (5) | 1 (4) | 0 (0) | 0.47 |
Bilateral lung transplant (%) | 26 (26) | 9 (24) | 8 (32) | 9 (25) | 0.75 |
Prior viral respiratory infection (%) | 6 (6) | 2 (5) | 3 (12) | 1 (3) | 0.38 |
Treatment for AR 3 months prior to inclusion (%) | 12 (12) | 9 (23) | 3 (12) | 0 (0) | < 0.01 |
Spirometric characteristics | |||||
Last FEV-1 (mL/s) | 1670 (1410–2100) | 1670 (1410–2210) | 1620 (1410–2100) | 1770 (1498–2062) | 0.49 |
BOS prior to enrollmenta (all stage) (%) | 13 (13) | 9 (24) | 3 (12) | 1 (3) | 0.02 |